Pharmacogenetics and Age-Related Macular Degeneration

Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration

Transpupilary thermotherapy of occult subfoveal choroidal neovascularization secondary to age related macular degeneration

 Abstract Background: Transpupillary thermotherapy is a new treatment for subfoveal choroidal neovascularization which needs further evaluation. This study was aimed to evaluate the efficacy of transpupillary thermotherapy on regression of occult subfoveal choroidal neovascularization with or without pigment epithelial detachment in patients with age-related macular degeneration. Methods: In a ...

همراهی پلی‌مورفیسم p.Gly119Arg ژن CFI در مبتلایان به بیماری دژنراسیون ماکولای وابسته به سن در جمعیت ساکن در شهر تهران

Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and is characterized by progressive degeneration of the retinal pigment epithelium and secondary photoreceptor loss, resulting in visual loss. Etiological research suggests that age related macular degeneration is a complex disease, caused by the interactions of several genetic and enviro...

مروری بر روش های کمک بینایی به منظور بهبود کیفیت زندگی بیماران مبتلا به دژنراسیون وابسته به سن ماکولا

Background and purpose: Age related macular degeneration is the most common cause of sever visual impairment and blindness among adults over the age of 65 years in developed countries. The purpose of this study was to review the literature on using low vision aids in age related macular degeneration and their effects on their quality of life. Materials and methods: A comprehensive search of ...

Pharmacogenetics and nutritional supplementation in age-related macular degeneration

The Age-Related Eye Disease Study (AREDS) recommended treatment with antioxidants plus zinc in patients with intermediate or advanced age-related macular degeneration in order to reduce progression risks. Recent pharmacogenetic studies have reported differences in treatment outcomes with respect to variants in genes for CFH and ARMS2, although the treatment recommendations based on these differ...